·
Trodelvy (sacituzumab govitecan-hziy) is a cytotoxic drug that is used at prescribed and recommended doses according to body weight to treat adults with triple-negative breast cancer.
Dose Calculation
- The recommended dose is 10mg/kg administered as an intravenous infusion once weekly on the first day and eighth day of a repeating 21-day cycle.
- Before giving TRODELVY, calculate the patient's weight before each treatment cycle( or more often if the patient's body weight has changed by more than 10% since the last infusion).
- Vials of the drug are allowed to sit at room temperature.
- A sterile syringe is used, and 20 mL of 0.9% sodium chloride injection, USP, is into each TRODELVY 180 mg vial, and the resulting concentration will be 10 mg/mL.
- Gently swirl the vial and let it dissolve for up to 15 minutes.
- Do not shake.
- It should be clear and yellow and should not have any particulates. One should not use the solution if it is cloudy or discolored.
- Use immediately after preparation and protect it from light.
- Continue treatment until the disease progresses or any unacceptable toxicity. Do not administer TRODELVY more than 10 mg/kg.
- Dosage form and Strength
- For injection: 180 mg of off-white to yellowish lyophilized powder in a single-dose vial.
Administration
Healthcare professionals give TRODELVY by drip into the vein since it's intravenous only. Its administration is done in steps.
- First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction.
- Subsequent Infusion: If the drug is tolerated in the first infusion, then a subsequent infusion of 1-2 hours has to be done, and after 30 minutes and during infusion, the patient should be observed for any reaction.
- Premedication:
Before the dose of TRODELVY (sacituzumab govitecan), prior medication to induce nausea and vomiting as a result of the infusion reaction and chemotherapy is recommended. - Anti-pyretics are given, which block H1 and H2 receptors before the infusion, are given as premedication, and the patient who has experienced previous adverse infusion reactions are given corticosteroids.
